
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc is positioned for sustained double-digit growth, supported by an increasing utilization of its light adjustable lens (LDD) technology within a growing installed base. The company demonstrated strong financial performance in 3Q25 by exceeding revenue consensus, while also raising its gross margin guidance for 2025 to 76-77%, indicating healthy operational efficiency. Additionally, RxSight's strategic initiatives to enhance engagement and drive LAL volumes further solidify its potential for positive financial outcomes.
Bears say
RxSight Inc. is facing a challenging outlook as evidenced by a decline in monthly utilization of light adjustable lenses (LALs), which fell from 8.7 in Q2 2025 to 8.0 in Q3 2025 and represents a year-over-year decrease from 10.1 in Q3 2024. Additionally, the company reported a 14% year-over-year decline in revenue to $30.3 million and a significant drop in the placements of light delivery devices (LDDs), down 68% year-over-year and 38% quarter-over-quarter, with only 25 LDDs placed in Q2 2025 against a consensus of 31. The company's risks are compounded by limited adoption of its technology due to the requirement for additional capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and the potential for future dilutive financing.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares